Zhou PY, Zhu DX, Chen YJ, Feng QY, Mao YH, Zhuang AB, Xu JM. High patatin like phospholipase domain containing 8 expression as a biomarker for poor prognosis of colorectal cancer. World J Gastrointest Oncol 2024; 16(3): 787-797 [PMID: 38577466 DOI: 10.4251/wjgo.v16.i3.787]
Corresponding Author of This Article
Jian-Min Xu, PhD, Professor, Surgeon, Department of General Surgery, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. xujmin@aliyun.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Peng-Yang Zhou, De-Xiang Zhu, Yi-Jiao Chen, Qing-Yang Feng, Yi-Hao Mao, Ao-Bo Zhuang, Jian-Min Xu, Department of General Surgery, Zhongshan Hospital Fudan University, Shanghai 200032, China
Author contributions: Zhou PY carried out the studies; Zhuang AB and Chen YJ participated in collecting data and drafted the manuscript; Mao YH and Feng QY performed statistical analysis and participated in its design; Zhu DX participated in acquisition, analysis, and interpretation of data and drafted the manuscript; all authors read and approved the final manuscript.
Institutional review board statement: This study was approved by the Clinical Research Ethics Committee of Zhongshan Hospital, Fudan University.
Informed consent statement: Informed consent was acquired from all patients of the primary cohort for the acquisition of clinical and pathological information and the use of surgical specimens.
Conflict-of-interest statement: The authors report having no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Min Xu, PhD, Professor, Surgeon, Department of General Surgery, Zhongshan Hospital Fudan University, No. 180 Fenglin Road, Shanghai 200032, China. xujmin@aliyun.com
Received: August 22, 2023 Peer-review started: August 22, 2023 First decision: November 21, 2023 Revised: December 19, 2023 Accepted: January 22, 2024 Article in press: January 22, 2024 Published online: March 15, 2024
Abstract
BACKGROUND
Patatin like phospholipase domain containing 8 (PNPLA8) has been shown to play a significant role in various cancer entities. Previous studies have focused on its roles as an antioxidant and in lipid peroxidation. However, the role of PNPLA8 in colorectal cancer (CRC) progression is unclear.
AIM
To explore the prognostic effects of PNPLA8 expression in CRC.
METHODS
A retrospective cohort containing 751 consecutive CRC patients was enrolled. PNPLA8 expression in tumor samples was evaluated by immunohistochemistry staining and semi-quantitated with immunoreactive scores. CRC patients were divided into high and low PNPLA8 expression groups based on the cut-off values, which were calculated by X-tile software. The prognostic value of PNPLA8 was identified using univariate and multivariate Cox regression analysis. The overall survival (OS) rates of CRC patients in the study cohort were compared with Kaplan-Meier analysis and Log-rank test.
RESULTS
PNPLA8 expression was significantly associated with distant metastases in our cohort (P = 0.048). CRC patients with high PNPLA8 expression indicated poor OS (median OS = 35.3, P = 0.005). CRC patients with a higher PNPLA8 expression at either stage I and II or stage III and IV had statistically significant shorter OS. For patients with left-sided colon and rectal cancer, the survival curves of two PNPLA8-expression groups showed statistically significant differences. Multivariate analysis also confirmed that high PNPLA8 expression was an independent prognostic factor for overall survival (hazard ratio HR = 1.328, 95%CI: 1.016-1.734, P = 0.038).
CONCLUSION
PNPLA8 is a novel independent prognostic factor for CRC. These findings suggest that PNPLA8 is a potential target in clinical CRC management.
Core Tip: Patatin like phospholipase domain containing 8 (PNPLA8) has been shown to be associated with a variety of cancers, but its role in the progression of colorectal cancer (CRC) is unclear. In this study, 751 consecutive CRC patients were retrospectively analyzed. The results of this study indicate that PNPLA8 is a new independent prognostic factor for CRC. High PNPLA8 expression in CRC leads to impaired survival. These findings suggest that PNPLA8 is a potential target for clinical CRC therapy, providing important insights to help personalize therapy for CRC patients.
